B-intervention	0	4	Site
I-intervention	5	7	of
I-intervention	8	15	primary
I-intervention	16	21	tumor
O	22	25	has
O	26	27	a
O	28	38	prognostic
O	39	43	role
O	44	46	in
O	47	55	operable
O	56	62	breast
O	63	69	cancer
O	69	70	:
O	71	74	the
O	75	88	international
O	89	95	breast
O	96	102	cancer
O	103	108	study
O	109	114	group
O	115	125	experience
O	125	126	.

O	127	133	Cancer
O	134	144	presenting
O	145	147	at
O	148	151	the
O	152	158	medial
O	159	163	site
O	164	166	of
O	167	170	the
O	171	177	breast
O	178	181	may
O	182	186	have
O	187	188	a
O	189	194	worse
O	195	204	prognosis
O	205	213	compared
O	214	218	with
O	219	225	tumors
O	226	233	located
O	234	236	in
O	237	245	external
O	246	255	quadrants
O	255	256	.

O	257	260	For
O	261	267	medial
O	268	274	tumors
O	274	275	,
O	276	284	axillary
O	285	290	lymph
O	291	295	node
O	296	303	staging
O	304	307	may
O	308	311	not
O	312	322	accurately
O	323	330	reflect
O	331	334	the
O	335	345	metastatic
O	346	355	potential
O	356	358	of
O	359	362	the
O	363	370	disease
O	370	371	.

B-total-participants	372	377	Eight
I-total-participants	377	378	-
I-total-participants	378	386	thousand
I-total-participants	387	391	four
I-total-participants	391	392	-
I-total-participants	392	399	hundred
I-total-participants	400	406	twenty
I-total-participants	406	407	-
I-total-participants	407	410	two
O	411	419	patients
O	420	428	randomly
O	429	437	assigned
O	438	440	to
O	441	454	International
O	455	461	Breast
O	462	468	Cancer
O	469	474	Study
O	475	480	Group
O	481	489	clinical
O	490	496	trials
O	497	504	between
O	505	509	1978
O	510	513	and
O	514	518	1999
O	519	523	were
O	524	534	classified
O	535	537	as
B-intervention	538	544	medial
I-intervention	545	549	site
O	550	551	(
B-intervention-participants	551	552	1
I-intervention-participants	552	553	,
I-intervention-participants	553	556	622
O	556	557	;
O	558	560	19
O	560	561	%
O	561	562	)
O	563	565	or
B-control	566	573	lateral
I-control	573	574	,
I-control	575	582	central
I-control	582	583	,
I-control	584	587	and
I-control	588	593	other
I-control	594	599	sites
O	600	601	(
B-control-participants	601	602	6
I-control-participants	602	603	,
I-control-participants	603	606	800
O	606	607	;
O	608	610	81
O	610	611	%
O	611	612	)
O	612	613	.

O	614	620	Median
O	621	627	follow
O	627	628	-
O	628	630	up
O	631	634	was
O	635	637	11
O	638	643	years
O	643	644	.

O	645	646	A
O	647	660	statistically
O	661	672	significant
O	673	683	difference
O	684	687	was
O	688	696	observed
O	697	700	for
O	701	709	patients
O	710	714	with
O	715	721	medial
O	722	728	tumors
O	729	735	versus
O	736	741	those
O	742	746	with
O	747	756	nonmedial
O	757	763	tumors
O	764	766	in
B-outcome	767	774	disease
I-outcome	774	775	-
I-outcome	775	779	free
I-outcome	780	788	survival
O	789	790	(
B-outcome	790	793	DFS
I-outcome	793	794	;
I-outcome	795	797	10
I-outcome	797	798	-
I-outcome	798	802	year
I-outcome	803	806	DFS
O	806	807	,
B-iv-bin-percent	808	810	46
I-iv-bin-percent	810	811	%
O	812	813	v
B-cv-bin-percent	814	816	48
I-cv-bin-percent	816	817	%
O	817	818	;
O	819	821	HR
O	821	822	,
O	823	824	1
O	824	825	.
O	825	827	10
O	827	828	;
O	829	831	95
O	831	832	%
O	833	835	CI
O	835	836	,
O	837	838	1
O	838	839	.
O	839	841	02
O	842	844	to
O	845	846	1
O	846	847	.
O	847	849	18
O	849	850	;
O	851	852	P
O	853	854	=
O	855	856	.
O	856	858	01
O	858	859	)
O	860	863	and
B-outcome	864	871	overall
I-outcome	872	880	survival
O	881	882	(
B-outcome	882	884	10
I-outcome	884	885	-
I-outcome	885	889	year
I-outcome	890	892	OS
B-iv-bin-percent	893	895	59
I-iv-bin-percent	895	896	%
O	897	898	v
B-cv-bin-percent	899	901	61
I-cv-bin-percent	901	902	%
O	902	903	;
O	904	906	HR
O	906	907	,
O	908	909	1
O	909	910	.
O	910	912	09
O	912	913	;
O	914	915	1
O	915	916	.
O	916	918	01
O	919	921	to
O	922	923	1
O	923	924	.
O	924	926	19
O	926	927	;
O	928	929	P
O	930	931	=
O	932	933	.
O	933	935	04
O	935	936	)
O	936	937	.

O	938	942	This
O	943	953	difference
O	954	963	increased
O	964	969	after
O	970	980	adjustment
O	981	984	for
O	985	990	other
O	991	1001	prognostic
O	1002	1009	factors
O	1010	1011	(
O	1011	1013	HR
O	1013	1014	,
O	1015	1016	1
O	1016	1017	.
O	1017	1019	22
O	1019	1020	;
O	1021	1023	95
O	1023	1024	%
O	1025	1027	CI
O	1027	1028	,
O	1029	1030	1
O	1030	1031	.
O	1031	1033	13
O	1034	1036	to
O	1037	1038	1
O	1038	1039	.
O	1039	1041	32
O	1042	1045	for
B-outcome	1046	1049	DFS
O	1049	1050	;
O	1051	1054	and
O	1055	1057	HR
O	1057	1058	,
O	1059	1060	1
O	1060	1061	.
O	1061	1063	24
O	1063	1064	;
O	1065	1067	95
O	1067	1068	%
O	1069	1071	CI
O	1071	1072	,
O	1073	1074	1
O	1074	1075	.
O	1075	1077	14
O	1078	1080	to
O	1081	1082	1
O	1082	1083	.
O	1083	1085	35
O	1086	1089	for
B-outcome	1090	1092	OS
O	1092	1093	;
O	1094	1098	both
O	1099	1100	P
O	1101	1102	=
O	1103	1104	.
O	1104	1108	0001
O	1108	1109	)
O	1109	1110	.

O	1111	1114	The
B-outcome	1115	1119	risk
I-outcome	1120	1122	of
I-outcome	1123	1130	relapse
O	1131	1134	for
O	1135	1143	patients
O	1144	1148	with
O	1149	1155	medial
O	1156	1168	presentation
O	1169	1172	was
O	1173	1180	largest
O	1181	1184	for
O	1185	1188	the
O	1189	1193	node
O	1193	1194	-
O	1194	1202	negative
O	1203	1209	cohort
O	1210	1213	and
O	1214	1217	for
O	1218	1226	patients
O	1227	1231	with
O	1232	1238	tumors
O	1239	1245	larger
O	1246	1250	than
O	1251	1252	2
O	1253	1255	cm
O	1255	1256	.

O	1257	1259	In
O	1260	1263	the
O	1264	1272	subgroup
O	1273	1275	of
O	1276	1277	2
O	1277	1278	,
O	1278	1281	931
O	1282	1290	patients
O	1291	1295	with
O	1296	1304	negative
O	1305	1313	axillary
O	1314	1319	lymph
O	1320	1325	nodes
O	1325	1326	,
B-outcome	1327	1329	10
I-outcome	1329	1330	-
I-outcome	1330	1334	year
I-outcome	1335	1338	DFS
O	1339	1342	was
B-iv-bin-percent	1343	1345	61
I-iv-bin-percent	1345	1346	%
O	1347	1348	v
B-cv-bin-percent	1349	1351	67
I-cv-bin-percent	1351	1352	%
O	1352	1353	,
O	1354	1357	and
B-outcome	1358	1360	OS
O	1361	1364	was
B-iv-bin-percent	1365	1367	73
I-iv-bin-percent	1367	1368	%
O	1369	1370	v
B-cv-bin-percent	1371	1373	80
I-cv-bin-percent	1373	1374	%
O	1375	1378	for
O	1379	1385	medial
O	1386	1392	versus
O	1393	1402	nonmedial
O	1403	1408	sites
O	1408	1409	,
O	1410	1422	respectively
O	1423	1424	(
O	1424	1426	HR
O	1427	1428	1
O	1428	1429	.
O	1429	1431	33
O	1431	1432	;
O	1433	1435	95
O	1435	1436	%
O	1437	1439	CI
O	1439	1440	,
O	1441	1442	1
O	1442	1443	.
O	1443	1445	15
O	1446	1448	to
O	1449	1450	1
O	1450	1451	.
O	1451	1453	54
O	1453	1454	;
O	1455	1456	P
O	1457	1458	=
O	1459	1460	.
O	1460	1464	0001
O	1465	1468	for
B-outcome	1469	1472	DFS
O	1472	1473	;
O	1474	1477	and
O	1478	1480	HR
O	1481	1482	1
O	1482	1483	.
O	1483	1485	40
O	1485	1486	;
O	1487	1489	95
O	1489	1490	%
O	1491	1493	CI
O	1493	1494	,
O	1495	1496	1
O	1496	1497	.
O	1497	1499	17
O	1500	1502	to
O	1503	1504	1
O	1504	1505	.
O	1505	1507	67
O	1507	1508	;
O	1509	1510	P
O	1511	1512	=
O	1513	1514	.
O	1514	1518	0003
O	1519	1522	for
B-outcome	1523	1525	OS
O	1525	1526	)
O	1526	1527	.

O	1528	1533	Tumor
O	1534	1538	site
O	1539	1542	has
O	1543	1544	a
O	1545	1556	significant
O	1557	1567	prognostic
O	1568	1575	utility
O	1575	1576	,
O	1577	1587	especially
O	1588	1591	for
O	1592	1600	axillary
O	1601	1606	lymph
O	1607	1611	node
O	1611	1612	-
O	1612	1620	negative
O	1621	1628	disease
O	1628	1629	,
O	1630	1634	that
O	1635	1641	should
O	1642	1644	be
O	1645	1655	considered
O	1656	1658	in
O	1659	1670	therapeutic
O	1671	1681	algorithms
O	1681	1682	.

O	1683	1686	New
O	1687	1694	staging
O	1695	1705	procedures
O	1706	1710	such
O	1711	1713	as
O	1714	1720	biopsy
O	1721	1723	of
O	1724	1727	the
O	1728	1736	sentinel
O	1737	1745	internal
O	1746	1753	mammary
O	1754	1759	nodes
O	1760	1762	or
O	1763	1768	novel
O	1769	1776	imaging
O	1777	1784	methods
O	1785	1791	should
O	1792	1794	be
O	1795	1802	further
O	1803	1810	studied
O	1811	1813	in
O	1814	1822	patients
O	1823	1827	with
O	1828	1834	medial
O	1835	1841	tumors
O	1841	1842	.
